Curtis Thomas Harris

US Patent:

7348139, Mar 25, 2008

Filed:

Apr 15, 2002

Appl. No.:

10/123882

Inventors:

James G. Herman - Lutherville MD, US
Hirohide Yoshikawa - Tokyo, JP
Curtis C. Harris - Garrett Park MD, US

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C18Q 1/68

US Classification:

435 6

Abstract:

Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods.

US Patent:

7749709, Jul 6, 2010

Filed:

Feb 22, 2008

Appl. No.:

12/036182

Inventors:

James G. Herman - Lutherville MD, US
Hirohide Yoshikawa - Tokyo, JP
Curtis C. Harris - Garrett Park MD, US

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods.

US Patent:

20100297655, Nov 25, 2010

Filed:

Jul 6, 2010

Appl. No.:

12/831176

Inventors:

James G. Herman - Lutherville MD, US
Hirohide Yoshikawa - Tokyo, JP
Curtis C. Harris - Garrett Park MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods.

US Patent:

53427777, Aug 30, 1994

Filed:

Mar 3, 1992

Appl. No.:

7/844873

Inventors:

Katharine H. Cole - Dayton MD
John F. Lechner - Bethesda MD
Curtis C. Harris - Bethesda MD

Assignee:

The United States of America as represented by the Secretary of the
Dept. of Health and Human Services - Washington DC

International Classification:

C12N 100
C12N 500
C12N 1500
C12Q 100

US Classification:

43524031

Abstract:

The present invention relates to cell medium developed to support long term multiplication and permanent establishment of a cell line of human liver epithelial cells. The medium may contain an effective cell growth promoting amount of calcium ions; an effective cell growth promoting amount of glucose; an effective amount of insulin to aid cells in glucose uptake; an effective cell growth promoting amount of hydrocortisone; an effective amount of epidermal growth factor to bind epidermal growth factor receptors on cells; an effective amount of transferrin to increase DNA synthesis in cells; an effective amount of cholera toxin to increase DNA synthesis in cells; an effective amount of triiodothyronine to increase DNA synthesis in cells; and an effective growth promoting amount of mammalian hormones and mitogenic factors, including lipoprotein, cholesterol, phospholipids and fatty acids.

US Patent:

55299202, Jun 25, 1996

Filed:

May 1, 1992

Appl. No.:

7/879165

Inventors:

Katharine H. Cole - Dayton MD
John F. Lechner - Bethesda MD
Roger Reddel - Camperdown, AU
Curtis C. Harris - Bethesda MD
Andrea M. Pfeifer - Pyrbaum, DE

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

C12N 506
C12N 510
C12Q 102
A01N 6300

US Classification:

4352402

Abstract:

The present invention relates to long term multiplication and permanent establishment of a cell line of human liver epithelial cells(hepatocytes). The human liver epithelial cell line is capable of mitotically proliferating and continuously growing in vitro under suitable environmental conditions in suitable culture media. A method of producing an immortalized human liver epithelial cell line is also disclosed. The invention also relates to serum-free cell medium developed to support long term multiplication and permanent establishment of a cell line of human liver epithelial cells. The medium may contain an effective cell growth promoting amount of calcium ions; an effective cell growth promoting amount of glucose; an effective amount of insulin to aid cells in glucose uptake; an effective cell growth promoting amount of hydrocortisone; an effective amount of epidermal growth factor to bind epidermal growth factor receptors on cells; an effective amount of transferrin to increase DNA synthesis in cells; an effective amount of cholera toxin to increase DNA synthesis in cells; an effective amount of triiodothyronine to increase DNA synthesis in cells; and an effective growth promoting amount of mammalian hormones and mitogenic factors, including lipoprotein, cholesterol, phospholipids and fatty acids.

US Patent:

46083391, Aug 26, 1986

Filed:

Oct 25, 1983

Appl. No.:

6/545257

Inventors:

George H. Yoakum - Gaithersburg MD
Curtis C. Harris - Bethesda MD
Brent E. Korba - Laurel MD
John F. Lechner - Wheaton MD

International Classification:

C12N 1500
C12N 500
C12P 2102

US Classification:

4351722

Abstract:

A modified protoplast fusion method and cell line is disclosed that stably transfects human cells with pSV2-derived plasmids at frequencies greater than 10. sup. -3. This procedure makes it possible to test the biological effect of individual genes (i. e. , oncogenes and other cellular genes, and viral genes). To demonstrate the utility of this invention, a pSV2gpt. sup. + plasmid constructed to carry a subgenomic fragment of hepatitis B virus (HBV) that contained the core antigen gene (HBc gene) is transfected into human cells. Human cell lines are stably transfected with the HBC. sup. + gene by selecting recipient cells for expression of guanine phosphoribosyl transferase expression; other selective markers, i. e. , neomycin resistance, can also be used. Conditions for enhancing the expression of the transfected gene(s) have also been developed.